In last trading session, Candel Therapeutics Inc (NASDAQ:CADL) saw 1.4 million shares changing hands with its beta currently measuring -0.94. Company’s recent per share price level of $5.31 trading at -$0.26 or -4.67% at ring of the bell on the day assigns it a market valuation of $250.82M. That closing price of CADL’s stock is at a discount of -174.95% from its 52-week high price of $14.60 and is indicating a premium of 70.62% from its 52-week low price of $1.56. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.42 million shares which gives us an average trading volume of 1.25 million if we extend that period to 3-months.
For Candel Therapeutics Inc (CADL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Upright in the red during last session for losing -4.67%, in the last five days CADL remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $5.31 price level, adding 31.04% to its value on the day. Candel Therapeutics Inc’s shares saw a change of -38.82% in year-to-date performance and have moved -29.20% in past 5-day. Candel Therapeutics Inc (NASDAQ:CADL) showed a performance of -32.61% in past 30-days. Number of shares sold short was 3.45 million shares which calculate 2.5 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -43.86% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 13.60% while estimates for its earnings growth in next 5 years are of 16.34%.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Insiders are in possession of 18.54% of company’s total shares while institution are holding 44.13 percent of that, with stock having share float percentage of 54.18%. Investors also watch the number of corporate investors in a company very closely, which is 44.13% institutions for Candel Therapeutics Inc that are currently holding shares of the company. NORTHPOND VENTURES, LLC is the top institutional holder at CADL for having 1.94 million shares of worth $12.0 million. And as of 2024-06-30, it was holding 6.477 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.82 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.8035 of outstanding shares, having a total worth of $5.08 million.
